Taysha Gene Therapies, Inc. announced that it has entered into agreement for a private placement of common shares share for proceeds of $80,000,000 on October 21, 2022. The transaction will include participation from Astellas Pharma Inc. for 15% stake and Audentes Therapeutics, Inc. for 7,266,342 shares for proceeds of $30,009,992.46. The securities are subject to Regulation D.
Audentes Therapeutics, Inc.
Equities
US05070R1041
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+38.61% | 12.63B | |
+313.59% | 8.49B |